Navigation Links
Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
Date:10/13/2008

FirstVue(TM) HBSAG Test Found to Have Higher Sensitivity and Specificity than Other Rapid HBSAG Tests and FirstVue(TM) '...and was the preferred

test in all phases of this evaluation'

CORAL SPRINGS, Fla., Oct. 13 /PRNewswire/ -- AT First Diagnostic LLC an emerging worldwide marketing leader in rapid diagnostic test kits, today announced that a recent evaluation conducted by the Walter Reed Army Institute of Research of the FirstVue(TM) HBSAG Test, was released at the Advanced Technology Applications for Combat Casualty Care meeting, sponsored by the Department of Defense. The purpose of the evaluation, entitled "Laboratory Evaluation of Hepatitis B Rapid Test for Use in Screening Walking Blood Bank Donors," was to determine the best rapid HBSAG test to use for screening blood donors for Hepatitis B ("HBSAG") in the theater of war. The FirstVue(TM) HBSAG test was selected as the preferred test based on all facets of the study evaluation.

Out of all manufactures in the rapid diagnostic industry, six rapid tests were initially selected based on an evaluation of published claims and sensitivity testing using HBSAG positive samples. Those tests were then compared in a comprehensive evaluation of test performance using plasma and blood specimens. The study indicated that the FirstVue(TM) HBSAG test had the highest sensitivity (95.4%) and the highest specificity (99.7%) among all the tests evaluated. In addition, the evaluation indicated that the FirstVue(TM) HBSAG test detected HBSAG antibodies approximately three days sooner than available laboratory-based enzyme immunoassays. Early detection of seroconversion is an important measure of the sensitivity of a test and means that Hepatitis B infection can now be identified even with relatively recent exposure.

"We are very pleased with the results of the Walter Reed evaluation, it's just another confirmation of the quality of our product line and of the HBSAG rapid test we ar
'/>"/>

SOURCE AT First Diagnostic LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
2. What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
5. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
10. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
11. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... , NEW YORK, Nov. 20 Reportlink... is available in its catalogue. ,, Global Mark... http://www.reportlinker.com/p0164742/Global-Mark...m_source=prnewswire&utm_medium=pr&utm_camp...d Reproduction covers the U.S., 15 Countries in Eu...
(Date:11/20/2009)...MINNEAPOLIS, Nov. 20 Bio...lts for its first quarter ended September 30, 2009...ed share, on revenues of $3,263,000. This compare...d share, on revenues of $3,168,000 for the first q... quarter results, Biotel President and CEO Steve S...
(Date:11/20/2009)... FRANKLIN LAKES, N.J., Nov. 20 /PRNewswire-FirstCa... BDX ) today announced the completion of its acqui...ased company that develops and manufactures molecu..., In May 2009, BD and HandyLab announced an excl...e molecular assays on the HandyLab Jaguar(TM) plat...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Assisted Reproductive Devices 2009 2Biotel Announced Profitable First Quarter Ended September 30, 2009 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 52593 1Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 52593 2Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 52593 3Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 52593 4As the Government Continues to Work Toward Health Care Reform Medtipster is Providing a Free Solution to Rising Health Care Costs for Americans Right 52591 1As the Government Continues to Work Toward Health Care Reform Medtipster is Providing a Free Solution to Rising Health Care Costs for Americans Right 52591 2Human cells secrete cancer killing protein UK study finds 52589 1Human cells secrete cancer killing protein UK study finds 52589 2
...gimen yielded nearly double SVR rate compared to s... protease inhibitor SCH 900518 presented at EASL a...Schering-Plough Corporation (NYSE: SGP ) today r...dy showed boceprevir, its investigational oral hep...eginterferon alfa-2b and ribavirin, significantly ...
...ducation Online Activity and Podcast for Nurses an... lymphoblastic leukemia (ALL) is a complex heterog... in the treatment of pediatric patients, is often ...fessionals who treat adult patients with ALL to ma...e of factors affecting management options for this...
Other Medicine Technology:Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12Expert Insights in Acute Lymphoblastic Leukemia: Current Challenges and Future Directions 2
(Date:11/21/2009)..., , LONDON, November 21, 2009 /PRNewswire-...est Test Test Test Test Test Test Test Test Test T...est Test Test Test Test Test Test,Test Test Test T... More test More test More test More test More ...test More test More test More test More test More,...
(Date:11/21/2009)... Innovative medical apparel...onference , San Clemente,..., maker of breakthrough medical apparel, today ann...e on display at Medica 2009, a leading internation...seldorf, Germany. Medelita inaugurates its men,s c...
(Date:11/21/2009)... Eric J. Hall, president an...ation of America (AFA) issued the following statem...t detection as part of the new annual wellness for...ction and Affordable Care Act" that was intro...ork, NY (PRWEB) November 21, 2009 -- Eric J. Hall,...
(Date:11/21/2009)... Linwood Group ask whether ...an it be measured? , Lond...reveal that with up to one in three of the adult U...isk of developing alcohol-related liver disease*, ... turning to rehabilitation programmes and resident...
(Date:11/20/2009)..., , PRINCETON, NJ, Nov. 20 /PRNewswire-First...day that a Special Meeting of Shareholders will be... the Meeting is to consider approval of two specia...approve and authorize the sale of all or substanti...n the terms provided for in the asset purchase agr...
Breaking Medicine News(10 mins):Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3
...07 The Journal of the American Dental Association...ournals today in publishing a global theme issue o...collaborative effort among the worlds biomedical p...he world of articles on povertys devastating effec...
...wswire/ - IntelliPharmaCeutics Ltd. (the,"Company"... generic drug,commercialization activities. In la...any,s operating,affiliate IntelliPharmaCeutics Cor...plication (known as an ANDA) for a,drug product it...
...ng of Innovative Hypotheses, NEW YORK, Oct. 22 T...e selection of its 6th round of Novel Research,Gra...primed to explore,entirely new ideas on why the lu...oneering innovative lupus research. The outlay of...
...fth largest journal publisher, is proud to be part...uman Development launched today by the Council of ...s to raise awareness and stimulate interest and de... simultaneously publish papers on this topic, enab...
...er 22, 2007) A new study shows that obstacles to ... vary with age. The study presented at CHEST 2007,... of the American College of Chest Physicians (ACCP...e 65 reported cigarette cost and tobacco odor as r...
...Autism in California Lack Proper Healthcare Covera...,Area Chapter of Autism Speaks today announced the...slative Blue Ribbon Commission on,Autism,s recomme... the California State Legislature and Governor,Arn...
Other Medicine News:Health News:Journal of the American Dental Association spotlights poverty 2Health News:IntelliPharmaCeuitics Ltd. Announces Generic Drug Commercialization Activities 2Health News:New Round of Lupus Research Institute Awards Brings Promise of More Breakthroughs 2Health News:New Round of Lupus Research Institute Awards Brings Promise of More Breakthroughs 3Health News:New Round of Lupus Research Institute Awards Brings Promise of More Breakthroughs 4Health News:9 SAGE journals participate in global theme issue on poverty and human development 2Health News:Age affects motivation for quitting smoking 2Health News:San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism 2Health News:San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism 3
Liquid Trap
...d Transfer Kit High resolution ,transfer of DNA an...lary transfer allows for,alkaline buffer transfers... hours. , Economical Reusable blotting device re...refill packs available., Compact ,TurboBlotter h...
... using the Antigen-Antibody Pens-Using a proprieta...eveloped specialized fountain pens, called Antigen...deliver or write/mark the blotting membranes in an...tigen-bonded colored dyes helps to see antigen bei...
... using the Antigen-Antibody Pens-Using a proprieta...eveloped specialized fountain pens, called Antigen...deliver or write/mark the blotting membranes in an...tigen-bonded colored dyes helps to see antigen bei...
Medicine Products: